GB2104382A - Pharmaceutical formulations comprising human insulin and human C-peptide - Google Patents
Pharmaceutical formulations comprising human insulin and human C-peptide Download PDFInfo
- Publication number
- GB2104382A GB2104382A GB08224484A GB8224484A GB2104382A GB 2104382 A GB2104382 A GB 2104382A GB 08224484 A GB08224484 A GB 08224484A GB 8224484 A GB8224484 A GB 8224484A GB 2104382 A GB2104382 A GB 2104382A
- Authority
- GB
- United Kingdom
- Prior art keywords
- human
- insulin
- peptide
- composition
- human insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 title claims abstract description 49
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 title claims abstract description 45
- 101000976075 Homo sapiens Insulin Proteins 0.000 title claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 58
- 102000007327 Protamines Human genes 0.000 claims description 10
- 108010007568 Protamines Proteins 0.000 claims description 10
- 229940048914 protamine Drugs 0.000 claims description 6
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 52
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 102000004877 Insulin Human genes 0.000 description 26
- 108090001061 Insulin Proteins 0.000 description 26
- 229940125396 insulin Drugs 0.000 description 24
- 108010076181 Proinsulin Proteins 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 229940069330 human zinc insulin Drugs 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000003054 hormonal effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 108010005991 Pork Regular Insulin Proteins 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 229950008679 protamine sulfate Drugs 0.000 description 4
- 239000011787 zinc oxide Substances 0.000 description 4
- 108010075254 C-Peptide Proteins 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 102000003670 Carboxypeptidase B Human genes 0.000 description 2
- 108090000087 Carboxypeptidase B Proteins 0.000 description 2
- 241001202975 Isophanes Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101500025353 Homo sapiens Insulin A chain Proteins 0.000 description 1
- 101500025354 Homo sapiens Insulin B chain Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010059605 Necrobiosis Diseases 0.000 description 1
- 208000015906 Necrobiotic disease Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- -1 sodium hydroxide Chemical compound 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
A pharmaceutical composition is disclosed which comprises, in association with a pharmaceutically acceptable carrier, human insulin and human C-peptide in a molar ratio, human insulin to human C- peptide, of from about 1:4 to about 4:1.
Description
SPECIFICATION
Pharmaceutical formulations comprising human insulin and human C-peptide.
Diabetes mellitus is a metabolic disorder characterized by the failure of body tissues to oxidize carbohydrates at the normal rate. Its most important factor is a deficiency of insulin. During the last 60 years people suffering from diabetes have been greatly aided by receiving controlled amounts of insulin. To the present time, the insulin used by diabetics has been isolated from animal pancreases, generally bovine and porcine. Both bovine and porcine insulin differ structurally from insulin generated by the human pancreas. Recently, it has become possible, by recombinant DNA methodology, to produce insulin identical to that produced by the human pancreas. The use of such insulin will enable the diabetic to more closely mimic the natural system than heretofore has been possible.
Nevertheless, it long has been recognized that administration of insulin to the diabetic is alone insufficient to restore and/or maintain the normal metabolic state. Although insulin has its manifested effect on carbohydrate metabolism, diabetes mellitus carries additional disorders, most if not all of which are related to the structure and function of blood vessels. The deficiences leading to these disorders rarely are completely corrected by conventional insulin therapy.
Those vascular abnormalities associated with diebetes often are referred to as "complications of diabetes". They consist generally of microangiopathic changes resulting in lesions in the retina and the kidney. Neuropathy represents an additional diabetic complication which may or may not be related directly or indirectly to the noted microangiopathic changes.Examples of specific manifestations of diabetes complications are (1) diseases of the eye, including retinopathy, cataract formation, glaucoma, and extraocular muscle palsies; (2) diseases of the mouth, including gingivitis, increased incidence of dental caries, periodontal disease, and greater resorption of the alveolar bone; (3) motor, sensory, and autonomic neuropathy; (4) largevessel disease; (5) microangiopathy; (6) diseases of the skin, including xanthoma diabeticorum, necrobiosis lipoidca diabeticorum, furunculosis, mycosis, and pruritis; (7) diseases of the kidneys, including diabetic glomeulosclerosis, arteriolar nephrosclerosis, and pylonephritis; and (8) problems during pregnancy, including increased incidence of large babies, stillbirths, miscarriages, neonatal deaths, and congentital defects.
Many, and perhaps all, of the diabetic complications are the result of the failure of insulin alone to restore the body to its natural hormonal balance.
This invention is directed to pharmaceutical compositions that more nearly achieve and maintain natural hormonal homeostatis in a diabetic state than can be achieved by adminstration of insulin alone.
Thus, this invention concerns a pharmaceutical composition which comprises, in association with a pharmaceuticaily acceptable carrier, human insulin and human C-peptide in a ratio on a molar basis, human insulin to human C-peptide, of from about 1:4 to about 4:1.
The two essential constituents of the pharmaceutical compositions of this invention are human insulin and human C-peptide.
Human insulin is available via a variety of routes, including organic synthesis, isolation from human pancreas, conversion of human proinsulin, conversion of isolated animal insulin, and, more recently, recombient DNA methodology.
Using recombinant DNA methodology, human insulin can be prepared by the separate expression and isolation of human insulin A-chain and human insulin B-chain followed by their proper disulfide bond formation. Alternatively, the recombinant DNA expression product can be human proinsulin itself or a human proinsulin precursor which is converted to human proinsulin.
The proinsulin then is enzymatically cleaved, for example, using trypsin and carboxypeptidase B, to produce human insulin.
Human insulin can also be prepared from porcine insulin. Human insulin differs from porcine insulin by a single amino acid, i.e. the B-chain carboxyl terminal amino acid. Alanine, the B-30 amino acid of porcine insulin, is cleaved and replaced by threonine. in this regard, see, for example, U.S. Patent No. 3,276,961.
The other active constituent of the composition of this invention, human C-peptide, is a portion of a peptide present in human proinsulin and to which the insulin A- and B-chains are joined. This peptide, termed a "connecting peptide", is removed during production of human insulin from proinsulin. The connecting peptide present in human proinsulin has the formula
Arg-Arg-G I u-Ala-Glu-Asp-Leu-G In-Val-G ly-Gln-Val-G lu-Leu-G Iy-Giy-Gly-Pro-Gly-Ala-Gly-Ser-Leu- Gln.Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln-Lys-Arg.
The human C-peptide present in the composition of this invention differs from the connecting peptide by elimination of four amino acids, two at each end. Thus, the human C-peptide has the structure Glu-Ala-Glu-Asp-Leu-G In-Val-G Iy-Gln-Val-Leu-G Iy-Gly-Gly-Pro-Gly-Pro-G Iy-Ala-Gly-Ser-Leu-Gln-Pro- Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln.
The human C-peptide constituent of the composition of this invention can be produced by chemical synthesis, see, e.g.. N. Yanaihara, C. Yanaihara. M. Sakagami, N. Sakura, T.
Hashimoto, and T. Nishida, Diabetes 27 (suppl. 1), 149-160 (1978), or from human proinsulin as a result of its cleavage to produce human insulin.
As noted, therefore, the active constituents of the composition of this invention are available via a variety of routes including human proinsulin. In broad outline, the production of insulin using recombient DNA methodology involves obtaining. whether by isolation, construction, or a combination of both, a sequence of DNA coding for the amino acid sequence of human proinsulin. The human proinsulin DNA then Is inserted in reading phase into a suitable cloning and expression vehicle. The vehicle is used to transform a suitable microorganism after which the transformed microorganism is subjected to fermentation conditions leading to (a) the production of additional copies of the proinsulin gene-consisting vector and (b) the expression of proinsulin or a proinsulin precursor product.
In the event the expression product Is a proinsulin precursor, it generally will comprise the human proinsulin amino acid sequence joined at its amino terminal end to a fragment of a protein normally expressed in the gene sequence into which the proinsulin gene has been inserted. The proinsulin amino acid sequence is joined to the protein fragment through a specifically cleavable site. typically methionine This product is customarily referred to as a fused gene product.
The proinsulin amino acid sequence is cleaved from the fused gene product using cyanogen bromide after which the cysteine sulfhydrl moietes of the proinsulin amino acid sequence are stabilized by conversion to their corresponding S-sulfonates.
The resulting proinsulin 5-sulfonate is puried. and the purified proinsulin S-sulfonate then is converted to proinsulin by formation of the three properly located disulfide bonds.
Upon purification of the proinsulin. it is enzymatically cleaved, typically using trypsin and carboxypeptidase B, resulting in formation of human insulin and human C-peptide.
The compositions of this invention contain human insulin and human C-peptide in a ratio, on a molar basis, of from about 1:4 to about 4:1 Preferably, the ratio of human insulin to human
C-peptide is from about 1 2 to about 2:1. and. most preferably, from about 1:1 to about 2:1.
As noted, the compositions of this invention are useful in promoting the attainment of natural hormonal homeostasis and thereby preventing or substantially diminishing or retarding those recognized diabetic complications. The amount of the compositions of this invention necessary to maintain natural hormonal homeostasis or to achieve a state that more nearly approaches natural hormonal homeostasis in the diabetic, of course, will depend upon the severity of the diabetic condition. Moreover, the amount will vary depending upon route of adminstration.
Uitimately, the amount of composition administered and the frequency of such administration will be at the discretion of the particular physician. In general, however, the dosage will be in the range affording from about 0.02 to about 5 units of human insulin per kilogram body weight per day, and, prefeably, from about 0.1 to about 1 unit of human insulin per kilogram body weight per day.
The composition is administered parentially, including subcutaneous, intramuscular, and intravenous. The compositions of this invention comprise the active ingredients, human insulin and human C-peptide, together with a pharmaceutically acceptable carrier therefor and, optionally, other therapeutic ingredients. The total amount of active ingredients present in the composition ranges from about 99.99 to about 0.01 percent by weight. The carrier must be acceptable in the sense that it is compatible with other components of the composition and is not deleterious to the recipient thereof.
Compositions of this invention suitable for parential adminstration conveniently comprise sterile aqueous solutions and/or suspensions of the pharmaceutically active ingredients, which solutions or suspensions preferably are made isotonic with the blood of the recipient, generally using sodium chloride, glycerin, glucose, mannitol, sorbitol, and similar known agents. In addition, the compositions may contain any of a number of adjuvants, such as buffers, preservatives, dispersing agents, agents that promote rapid onset of action, agents that promote prolonged duration of action, and other known agents. Typical preservatives are, for example, phenol, imcresol, methyl phydroxybenzoate, and others. Typical buffers are, for example, sodium phosphate, sodium acetate, sodium citrate, and others.
Moreover, an acid, such as hydrochloric acid, or a base, such as sodium hydroxide, can be used for pH adjustment. In general, the pH of the aqueous composition ranges from about 2 to about 8, and, preferably, from about 6.8 to about 8.0.
Other suitable additives are, for example, divalent zinc ion which, if present at all, is generally present in an amount from about 0.01 mg. to about 0.5 mg. per 100 units of human insulin, and protamine salt (for example, in the form of its sulfate), which, if present at all, is generally present in an amount from about 0.1 mg. to about 2 mg. per 100 units of human insulin.
Examples of particular pharmaceutical compositions of this invention are provided in the examples appearing herein below.
Example 1 - Neutral Regular Human Insulin:Human C-peptide Formulation [1:4 human insulin:human C-peptide on molar basis at 40 units (U) insulin per cubic centimeter(cc.)]
To prepare 10 cc. of the composition, mix
Human Zinc Insulin (28 U/mg.) 400 U
Human C-Peptide 30 mg.
Phenol, distilled 20 mg.
Glycerin 160 mg.
Water and either 10% hydrochloric acid or 10% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7.0-7.8.
Example 2 - Neutral regular Human Insulin:Human C-peptide Formulation [1:1 human insulin:human C-peptide on molar basis at 100 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Zinc Insulin (28 U/mg.) 1000 U
Human C-Peptide 1 9 mg.
Phenol, distilled 20 mg.
Glycerin 160 mg.
Water and either 10% hydrochloric acid or 10% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7-0-7.8.
Example 3- Protamine, Zinc Human Insulin:Human C-peptide Formulation [1:1 human insulin:human C-peptide on molar basis at 40 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Zinc Insulin (28 U/mg.) 400 U
Human C-Peptide 8 mg.
Phenol, distilled 25 mg.
Zinc Oxide 0.78 mg.
Glycerin 160 mg.
Protamine Sulfate 4.0-6.0 mg.
Sodium Phosphate, crystals 38 mg.
Water and either 10% hydrochloric acid or 10% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7.1-7.4.
Example 4 - Protamine, Zinc Human Insulin:Human C-Peptide Formulation [2:1 human insulin:human C-peptide on molar basis at 100 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Zinc Insulin (28 U/mg.) 1000 U
Human C-Peptide 9 mg.
Phenol, distilled 25 mg.
Zinc oxide 2.0 mg.
Glycerin 160 mg.
Protamine Sulfate 10-15 mg.
Sodium Phosphate, crystals 38 mg.
Water and either 10% hydrochloric acid or 10% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7.1-7.4.
Example 5- Isophane Protamine, Zinc Human Insulin:Human C-peptide Formulation [1:1 human insulin:human C-peptide on molar basis at 40 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Zinc Insulin (28 U/mg.) 400 U
Human C-Peptide 8 mg.
tmCresol, distilled 1 6 mg.
Phenol, distilled 6.5 mg.
Glycerin 160 mg.
Protamine Sulfate 1.2-2.4 mg.
Sodium Phosphate, crystals 38 mg.
Water and either 10% hydrochloric acid or 1 0% sodium hydroxide sufficient to make a composition volume of 10 cc and a final pH of 7.1-7.4.
Example 6 - Isophane Protamine. Zinc Human Insulin:Human C-Peptide Formulation [4:1 human insulin:human C-peptide on molar basis at 100 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Zinc Insulin (28 U/mg.) 1 000U
Human C-Peptide 5 mg.
mCresol, distilled 1 6 mg.
Phenol, distilled 6.5 mg.
Glycerin 160 mg.
Protamine Sulfate 3.0-6.0 mg.
Sodium Phosphate, Crystals 38 mg
Water and either 10% hydrochloric acid or 1 0% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7.1-7.4.
Example 7 - Zinc Human Insulin Suspension:Human C-Peptide Formulation [1:2 human insulin: human C-peptide on molar basis at 40 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Zinc Insulin (28 U/mg.) 400 U
Human C-Peptide 1 5 mg.
Sodium Acetate, Anhydrous 1 6 mg.
Sodium Chloride, Granular 70 mg.
Methyl p-Hyroxybenzoate 1 0 mg.
Zinc Oxide 0.63 mg.
Water and either 10% hydrochloric acid or 1 0% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7.2-7.5.
Example 8- Zinc Human Insulin Suspension:Human C-Peptide Formulation [1:1 human insulin:human C-peptide on molar basis at 100 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Zinc Insulin (28 U/mg.) 1000 U
Human C-Peptide 1 9 mg.
Sodium Acetate, Anhydrous 1 6 mg.
Sodium Chloride, Granular 70 mg.
Methyl p-Hydroxybenzoate 10 mg.
Zinc Oxide 1.6 mg.
Water and either 1 0% hydrochloric acid or 10% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7 2-7.5.
Example 9 - Neutral Regular Human Insulin:Human C-Peptide Formulation [1:4 human insulin:human C-peptide on molar basis at 40 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Sodium Insulin (28 U/mg.) 400 U
Human C-Peptide 30 mg.
Phenol, distilled 20 mg.
Glycein 160 mg.
Water and either 10% hydrochloric acid or 10% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7.0-7.8.
Example 10- Neutral Regular Human Insulin:Human C-Peptide Formulation [1:1 human insulin:human C-peptide on molar basis at 100 U insulin per cc.]
To prepare 10 cc. of the composition, mix
Human Sodium Insulin (28 U/mg.) 1000 U
Human C-Peptide 19 mg.
Phenol, distilled 20 mg.
Glycerin 160 mg.
Water and either 10% hydrochloric acid or 10% sodium hydroxide sufficient to make a composition volume of 10 cc. and a final pH of 7.0-7.8.
Claims (6)
1. A pharmaceutical composition which comprises, in association with a pharmaceutically acceptable carrier, human insulin and human C-peptide in a ratio on a molar basis, human insulin to human C-peptide, of from about 1:4 to about 4:1.
2. Composition of claim 1, in which the molar ratio of human insulin to human C-peptide is from about 1:2 to about 2:1.
3. Composition of claim 1, in which the molar ratio of human insulin to human C-peptide is from about 2:1.
4. Composition of claim 1, which contains divalent zinc ion.
5. Composition of claim 1, which contains protamine salt.
6. A pharmaceutical composition as claimed in claims 1 to 5, substantially as hereinbefore described with reference to any one of the examples.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29671581A | 1981-08-27 | 1981-08-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2104382A true GB2104382A (en) | 1983-03-09 |
| GB2104382B GB2104382B (en) | 1984-12-19 |
Family
ID=23143238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08224484A Expired GB2104382B (en) | 1981-08-27 | 1982-08-26 | Pharmaceutical formulations comprising human insulin and human c-peptide |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS5846024A (en) |
| AU (1) | AU551879B2 (en) |
| BE (1) | BE894185A (en) |
| CA (1) | CA1176158A (en) |
| CH (1) | CH650679A5 (en) |
| DE (1) | DE3232034A1 (en) |
| DZ (1) | DZ452A1 (en) |
| FR (1) | FR2513126B1 (en) |
| GB (1) | GB2104382B (en) |
| IE (1) | IE54119B1 (en) |
| IL (1) | IL66611A0 (en) |
| IT (1) | IT1153182B (en) |
| LU (1) | LU84359A1 (en) |
| MW (1) | MW3882A1 (en) |
| NL (1) | NL192192C (en) |
| NZ (1) | NZ201682A (en) |
| PH (1) | PH19361A (en) |
| SE (1) | SE460334B (en) |
| ZA (1) | ZA826159B (en) |
| ZW (1) | ZW17482A1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0132769A1 (en) * | 1983-07-22 | 1985-02-13 | Hoechst Aktiengesellschaft | Pharmaceutical formulation for the treatment of diabetes mellitus |
| EP0303308A1 (en) * | 1987-08-14 | 1989-02-15 | Akzo N.V. | Preparation for preventing or combating complications in diabetes |
| EP0265214A3 (en) * | 1986-10-20 | 1989-07-26 | Novo Nordisk A/S | Polypeptide preparation |
| EP0280534A3 (en) * | 1987-02-25 | 1990-01-31 | Novo-Nordisk A/S | Novel insulin derivatives |
| US5212154A (en) * | 1987-08-14 | 1993-05-18 | Akzo N.V. | Preparation for treating complications in diabetes |
| US5977068A (en) * | 1986-10-20 | 1999-11-02 | American Cyanamid Company | Stabilized growth hormone compositions |
| US6610649B2 (en) | 1996-09-27 | 2003-08-26 | Creative Peptides Sweden Ab | Insulin C-peptides |
| WO2006053906A1 (en) * | 2004-11-22 | 2006-05-26 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
| WO2007015069A3 (en) * | 2005-08-01 | 2007-04-19 | Creative Peptides Sweden Ab | Compositions for ameliorating a reduced higher brain function resulting from organic brain lesions |
| US20120178676A1 (en) * | 2010-05-17 | 2012-07-12 | Cebix, Inc. | Pegylated c-peptide |
| US8927489B2 (en) | 2005-06-02 | 2015-01-06 | Cebix Incorporated | Sustained release preparation of pro-insulin C-peptide |
| US8962553B2 (en) | 2011-11-17 | 2015-02-24 | Cebix Ab | Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0323979D0 (en) | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
| MX2011003117A (en) | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Polymer conjugates of therapeutic peptides. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2789080A (en) * | 1952-08-14 | 1957-04-16 | Christensen Henry Marinus | Insulin-albumin compositions |
| CH330318A (en) * | 1953-09-08 | 1958-05-31 | British Drug Houses Ltd | Process for the production of an insulin preparation with an extended duration of action |
-
1982
- 1982-08-23 CH CH5010/82A patent/CH650679A5/en not_active IP Right Cessation
- 1982-08-23 IL IL66611A patent/IL66611A0/en unknown
- 1982-08-23 ZW ZW174/82A patent/ZW17482A1/en unknown
- 1982-08-23 CA CA000409900A patent/CA1176158A/en not_active Expired
- 1982-08-24 DZ DZ826637A patent/DZ452A1/en active
- 1982-08-24 PH PH27772A patent/PH19361A/en unknown
- 1982-08-24 ZA ZA826159A patent/ZA826159B/en unknown
- 1982-08-24 BE BE6/47701A patent/BE894185A/en not_active IP Right Cessation
- 1982-08-24 NL NL8203315A patent/NL192192C/en not_active IP Right Cessation
- 1982-08-24 NZ NZ201682A patent/NZ201682A/en unknown
- 1982-08-24 MW MW38/82A patent/MW3882A1/en unknown
- 1982-08-25 JP JP57148494A patent/JPS5846024A/en active Pending
- 1982-08-25 FR FR8214595A patent/FR2513126B1/en not_active Expired
- 1982-08-25 AU AU87594/82A patent/AU551879B2/en not_active Expired
- 1982-08-25 SE SE8204873A patent/SE460334B/en not_active IP Right Cessation
- 1982-08-26 GB GB08224484A patent/GB2104382B/en not_active Expired
- 1982-08-26 LU LU84359A patent/LU84359A1/en unknown
- 1982-08-26 IE IE2064/82A patent/IE54119B1/en not_active IP Right Cessation
- 1982-08-27 DE DE19823232034 patent/DE3232034A1/en active Granted
- 1982-08-27 IT IT8223017A patent/IT1153182B/en active
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0132769A1 (en) * | 1983-07-22 | 1985-02-13 | Hoechst Aktiengesellschaft | Pharmaceutical formulation for the treatment of diabetes mellitus |
| EP0265214A3 (en) * | 1986-10-20 | 1989-07-26 | Novo Nordisk A/S | Polypeptide preparation |
| US5977068A (en) * | 1986-10-20 | 1999-11-02 | American Cyanamid Company | Stabilized growth hormone compositions |
| EP0280534A3 (en) * | 1987-02-25 | 1990-01-31 | Novo-Nordisk A/S | Novel insulin derivatives |
| EP0303308A1 (en) * | 1987-08-14 | 1989-02-15 | Akzo N.V. | Preparation for preventing or combating complications in diabetes |
| US5212154A (en) * | 1987-08-14 | 1993-05-18 | Akzo N.V. | Preparation for treating complications in diabetes |
| US6610649B2 (en) | 1996-09-27 | 2003-08-26 | Creative Peptides Sweden Ab | Insulin C-peptides |
| US8263551B2 (en) | 2004-11-22 | 2012-09-11 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
| WO2006053906A1 (en) * | 2004-11-22 | 2006-05-26 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
| CN101060856B (en) * | 2004-11-22 | 2011-01-19 | 诺和诺德公司 | Soluble, stable insulin-containing preparations |
| US8927489B2 (en) | 2005-06-02 | 2015-01-06 | Cebix Incorporated | Sustained release preparation of pro-insulin C-peptide |
| WO2007015069A3 (en) * | 2005-08-01 | 2007-04-19 | Creative Peptides Sweden Ab | Compositions for ameliorating a reduced higher brain function resulting from organic brain lesions |
| US8691755B2 (en) | 2010-05-17 | 2014-04-08 | Cebix Ab | Pegylated C-peptide |
| US8927488B2 (en) | 2010-05-17 | 2015-01-06 | Cebix, Inc. | Pegylated C-peptide |
| US20120178676A1 (en) * | 2010-05-17 | 2012-07-12 | Cebix, Inc. | Pegylated c-peptide |
| US8962553B2 (en) | 2011-11-17 | 2015-02-24 | Cebix Ab | Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide |
Also Published As
| Publication number | Publication date |
|---|---|
| CH650679A5 (en) | 1985-08-15 |
| DE3232034C2 (en) | 1991-04-11 |
| MW3882A1 (en) | 1984-07-11 |
| FR2513126A1 (en) | 1983-03-25 |
| ZA826159B (en) | 1984-04-25 |
| AU8759482A (en) | 1983-03-03 |
| DZ452A1 (en) | 2004-09-13 |
| FR2513126B1 (en) | 1986-04-18 |
| CA1176158A (en) | 1984-10-16 |
| AU551879B2 (en) | 1986-05-15 |
| SE8204873D0 (en) | 1982-08-25 |
| NL8203315A (en) | 1983-03-16 |
| DE3232034A1 (en) | 1983-03-10 |
| NL192192C (en) | 1997-03-04 |
| ZW17482A1 (en) | 1982-11-17 |
| SE8204873L (en) | 1983-02-28 |
| SE460334B (en) | 1989-10-02 |
| IE822064L (en) | 1983-02-27 |
| LU84359A1 (en) | 1983-02-28 |
| BE894185A (en) | 1983-02-24 |
| NL192192B (en) | 1996-11-01 |
| GB2104382B (en) | 1984-12-19 |
| PH19361A (en) | 1986-04-02 |
| IT8223017A0 (en) | 1982-08-27 |
| IL66611A0 (en) | 1982-12-31 |
| IT1153182B (en) | 1987-01-14 |
| IE54119B1 (en) | 1989-06-21 |
| JPS5846024A (en) | 1983-03-17 |
| NZ201682A (en) | 1985-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4652548A (en) | Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin | |
| CA1176161A (en) | Pharmaceutical formulations comprising human insulin and human proinsulin | |
| TWI301761B (en) | Zinc-free and low-zinc insulin preparations having improved stability | |
| ES2612468T3 (en) | Procedure for the preparation of insulin-zinc complexes | |
| CA1176158A (en) | Pharmaceutical formulations comprising human insulin and human c-peptide | |
| AU642665B2 (en) | Treatment of insulin-resistant diabetes | |
| JPWO2004037859A1 (en) | GLP-1 derivative and transmucosal absorption preparation thereof | |
| US4654324A (en) | Human proinsulin pharmaceutical formulations | |
| CA1176160A (en) | Human proinsulin pharmaceutical formulations | |
| CA1176159A (en) | Pharmaceutical formulations comprising human insulin, human c-peptide, and human proinsulin | |
| US6153581A (en) | Drug for recovering renal function | |
| US6303127B1 (en) | Treatment of disease states | |
| CA2237643C (en) | Therapeutic agent for acute hepatic failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE20 | Patent expired after termination of 20 years |
Effective date: 20020825 |